Bexion Pharmaceuticals Inc. is developing innovative cures for cancer. Founded in 2006 when technology was licensed from Cincinnati Children’s Hospital Medical Center, Bexion has developed a first-in-class biologic, BXQ-350, with a novel mechanism of action for targeting and eliminating tumor cells. Mechanism of action studies support potential efficacy across a broad range of tumors, while minimizing “off-target” effects.
Bexion’s leadership, including the founders, Drs. Ray Takigiku (CEO/President) and Kevin Xu (VP) have significant experience in drug discovery, development and market support of pharmaceuticals. They are supported by team members with advanced degrees in science and business, and multiple “best of breed” consultants and collaborators in toxicology, regulatory affairs, manufacturing and clinical research.
The National Cancer Institute (NCI) has awarded Bexion funding through three Phase I Small Business Innovation Research (SBIR) grants, 1 Phase II SBIR grant, and a Phase II Bridge grant to study cancer. The Company has been able to leverage these funds to attract significant private investment capital.
In July 2016 Bexion received FDA Clearance for the first Clinical Trial using BXQ-350 (IND 113203) to dose patients with cancer. Patients have been dosed at the University of Cincinnati Barrett Cancer Center, the University of New Mexico Cancer Center, University of Kentucky Markey Cancer Center, and the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).